BERLIN, Oct 6 (Reuters) – Shares in Bayer AG (BAYGn.DE) rose 2.5% in pre-market commerce on Wednesday after the German agricultural and prescribed drugs agency received its first trial over claims its Roundup weedkiller causes most cancers.
A California jury discovered that the herbicide was not a considerable trigger of a kid’s uncommon type of non-Hodgkin’s lymphoma, the corporate stated on Tuesday. The verdict is the fourth involving Roundup and the primary within the firm’s favor. learn extra
Roundup-related lawsuits have dogged Bayer because it acquired the model as a part of its $63 billion buy of agricultural seeds and pesticides maker Monsanto in 2018.